Amid the 'su­per­bug' cri­sis, a Big Phar­ma-backed fund scores a mea­ger raise for an­tibi­otics R&D. Is $140M near­ly enough?

Years af­ter Big Phar­ma aban­doned the an­tibi­otics space, a small syn­di­cate has raised $140 mil­lion to ad­dress the loom­ing threat of an­timi­cro­bial re­sis­tance — but is it too lit­tle, too late?

Back in Ju­ly, more than 20 biotechs — in­clud­ing heavy­weight play­ers Pfiz­er, Eli Lil­ly, No­vo Nordisk, Boehringer In­gel­heim, Bay­er Phar­ma­ceu­ti­cals, Mer­ck KGaA and the Amer­i­can Mer­ck — band­ed to­geth­er to help launch the AMR Ac­tion Fund. With an ini­tial $1 bil­lion, the fund set out to bring two to four new an­tibi­otics to pa­tients by 2030.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.